Weight Loss Steroid Powder Rimonabant CAS: 168273-06-1

Rimonabant

Basic information:


Description: 
Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking . Acomplia, along with CB1 receptors, reduces the EC system's over-activity. 
 
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.



Use: 
Rimonabant is a weight loss drug, can significantly reduce weight, reduce waist circumference and reduce risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the presence of clinical obesity or heart disease people at risk. 

Rimonabant as a new weight loss drug, can also be used to quit smoking. Not only lose weight, but also lower blood pressure, cholesterol and blood sugar, clinical study found that subjects taking one to two months later, the weight can be reduced on average six to eight kilograms.


Function:
Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. 
 
Rimonabant / Acomplia,Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
 
Rimonabant / Acomplia works by blocking endogenous from binding to neuronal CB1 receptors. The activation of these receptors by endogenous , such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.



Specification:
Dosage:

It is expected that the usual dose of  rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.

Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.

There are no data supporting the use of rimonabant in pediatric populations.

Rimonabant should not be given to patients with a known hypersensitivity to the agent or any compound found in the tablet formulation.

The drug is contraindicated in lactat-ing women and is not recommended for use in women who are pregnant.
  Rimonabant

Basic information:


Description: 
Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking . Acomplia, along with CB1 receptors, reduces the EC system's over-activity. 
 
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.



Use: 
Rimonabant is a weight loss drug, can significantly reduce weight, reduce waist circumference and reduce risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the presence of clinical obesity or heart disease people at risk. 

Rimonabant as a new weight loss drug, can also be used to quit smoking. Not only lose weight, but also lower blood pressure, cholesterol and blood sugar, clinical study found that subjects taking one to two months later, the weight can be reduced on average six to eight kilograms.


Function:
Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. 
 
Rimonabant / Acomplia,Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
 
Rimonabant / Acomplia works by blocking endogenous from binding to neuronal CB1 receptors. The activation of these receptors by endogenous , such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.



Specification:
Dosage:

It is expected that the usual dose of  rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.

Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.

There are no data supporting the use of rimonabant in pediatric populations.

Rimonabant should not be given to patients with a known hypersensitivity to the agent or any compound found in the tablet formulation.

The drug is contraindicated in lactat-ing women and is not recommended for use in women who are pregnant.
 

Sorafenib Intermediates

Dingmin Pharmaceutical supply Sorofenib API and Sorofenib Intermediates with high purity and best price. The main products CAS No are as follows:475207-59-1, 220000-87-3, 327-78-6, 284462-37-9. Sample can be sent if you request.COA will be along with the quote. Tech pack can be offered.

Welcome to do business with us. Please email to us directly.

Cas 475207-59-1,Sorofenib Intermediates,Api Sorafenib Tosylate

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com